Table 3.
Solicited systemic reactions
| WAO grade | Placebo | LPP | ||
|---|---|---|---|---|
| N = 177 | N = 368 | |||
| Events | Patient, n (%) | Events | Patient, n (%) | |
| Occurrence within 30 min of injection | ||||
| Any | 5 | 4 (2.3) | 49 | 37 (10.1) |
| Grade 1 | 5 | 4 (2.3) | 34 | 25 (6.8 |
| Grade 2 | 0 | 0 (0.0 | 13a | 13 (3.5) |
| Grade 3 | 0 | 0 (0.0) | 1b | 1 (0.3) |
| Grade 4 | 0 | 0 (0.0) | 1c | 1 (0.3) |
| Occurrence later than 30 min after injection | ||||
| Any | 4 | 4 (2.3) | 48 | 41 (11.1) |
| Grade 1 | 3 | 3 (1.7) | 44 | 37 (10.1) |
| Grade 2 | 1 | 1 (0.6) | 4 | 4 (1.1) |
Results are shown according to the treatment received. Reactions were graded according to the WAO scale.14
LPP, Lolium perenne peptides; WAO, World Allergy Organization.
a
Included one serious event of bronchospasm with dyspnea and wheezing, followed by generalized urticaria.
b
Included one serious event of conjunctival injection, throat clearing, and urticaria, followed by abdominal cramps, retrosternal pain, dyspnea, nausea, and extension of the urticaria.
c
Included one serious event of tightness of the chest, followed by dizziness and decreased blood pressure.